The stock of Omeros Corporation (OMER) has seen a 5.84% increase in the past week, with a 164.02% gain in the past month, and a 239.35% flourish in the past quarter. The volatility ratio for the week is 9.78%, and the volatility levels for the past 30 days are at 14.29% for OMER. The simple moving average for the last 20 days is 39.30% for OMER’s stock, with a simple moving average of 171.27% for the last 200 days.
Is It Worth Investing in Omeros Corporation (NASDAQ: OMER) Right Now?
Company’s 36-month beta value is 1.99.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OMER is 55.36M, and currently, short sellers hold a 19.37% ratio of that floaft. The average trading volume of OMER on December 06, 2024 was 694.85K shares.
OMER) stock’s latest price update
Omeros Corporation (NASDAQ: OMER)’s stock price has gone rise by 8.23 in comparison to its previous close of 11.10, however, the company has experienced a 5.84% increase in its stock price over the last five trading days. businesswire.com reported 2024-12-02 that SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), to be held December 7-10, 2024 in San Diego. The zaltenibart abstracts are directed to the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening hem.
Analysts’ Opinion of OMER
Many brokerage firms have already submitted their reports for OMER stocks, with Rodman & Renshaw repeating the rating for OMER by listing it as a “Buy.” The predicted price for OMER in the upcoming period, according to Rodman & Renshaw is $9 based on the research report published on November 14, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see OMER reach a price target of $2, previously predicting the price at $12. The rating they have provided for OMER stocks is “Neutral” according to the report published on December 08th, 2022.
BofA Securities gave a rating of “Underperform” to OMER, setting the target price at $3 in the report published on November 08th of the previous year.
OMER Trading at 103.57% from the 50-Day Moving Average
After a stumble in the market that brought OMER to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.82% of loss for the given period.
Volatility was left at 14.29%, however, over the last 30 days, the volatility rate increased by 9.78%, as shares surge +162.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +201.28% upper at present.
During the last 5 trading sessions, OMER rose by +4.05%, which changed the moving average for the period of 200-days by +184.24% in comparison to the 20-day moving average, which settled at $8.61. In addition, Omeros Corporation saw 267.37% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for OMER
Current profitability levels for the company are sitting at:
- -126.91 for the present operating margin
- 0.55 for the gross margin
The net margin for Omeros Corporation stands at -98.48. The total capital return value is set at -0.67. Equity return is now at value -576.33, with -45.98 for asset returns.
Based on Omeros Corporation (OMER), the company’s capital structure generated 1.59 points at debt to capital in total, while cash flow to debt ratio is standing at -0.37. The debt to equity ratio resting at -2.68. The interest coverage ratio of the stock is -6.9.
Currently, EBITDA for the company is -163.61 million with net debt to EBITDA at -1.27. When we switch over and look at the enterprise to sales, we see a ratio of 672.42. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.96.
Conclusion
In a nutshell, Omeros Corporation (OMER) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
